ESR1 and breast neoplasm: One similarity between these studies is the greater effectiveness generally observed for fulvestrant (200 mg/kg in mice) in endocrine therapy-resistant breast tumor models without ER mutations as compared to more recently developed SERDs administered at a BSA-calculated clinically relevant dose.